MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Mink Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.113 Good morning and welcome to NK Therapeutics' second quarter 2026 conference 00:00:05.113 -- 00:00:10.296 call and webcast. All participants will be in a listen-only mode until the question 00:00:10.296 -- 00:00:14.138 and answer session. Please note this event is being recorded. 00:00:14.138 -- 00:00:19.140 I would now like to turn the conference over to Stephanie Perdenacar from NK 00:00:19.140 -- 00:00:25.722 Therapeutics, NK Investor Relations. Stephanie, please go ahead. 00:00:26.563 -- 00:00:30.322 Thank you, Operator, and thank you all for joining us today. 00:00:30.322 -- 00:00:35.705 Today's call is being webcast and will be available on our website for replay. 00:00:35.705 -- 00:00:39.708 I'd like to remind you that this call will include forward-looking statements, including 00:00:39.708 -- 00:00:45.271 those related to our clinical development, regulatory and commercial plans, timelines 00:00:45.271 -- 00:00:49.154 for data releases, and partnership opportunities. 00:00:49.154 -- 00:00:53.056 These statements are subject to risks and uncertainties. 00:00:53.056 -- 00:00:58.820 Please refer to our SEC filings available on our website for a detailed description 00:00:58.820 -- 00:01:00.821 of these risks. 00:01:00.821 -- 00:01:06.666 Joining me today are Dr. Jennifer Buell, President and Chief Executive Officer, 00:01:06.666 -- 00:01:12.310 Dr. Terese Hammond, Head of Development, and Melissa Orilall, 00:01:12.310 -- 00:01:16.954 Principal Financial Officer. I'd like to turn the call over to Dr. 00:01:16.954 -- 00:01:19.817 Buell to highlight our progress from this quarter. 00:01:19.817 -- 00:01:22.117 Dr. Buell? 00:01:22.659 -- 00:01:27.022 Thank you, Stephanie. Good morning, and thank you for joining us. 00:01:27.022 -- ...